Vosoritide keeps achondroplastic children’s hopes high
12 Apr 2021
bởiAudrey Abella
Long-term administration of vosoritide, a potent stimulator of endochondral bone growth, led to persistent and stable growth outcomes in children aged 5–18 years with achondroplasia, according to the ongoing phase III extension study results presented at ENDO 2021.
